Aqr Capital Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Aqr Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $2,766 - $3,035	71 Added 0.36%	19,816 $810,000
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $6,826 - $7,226	167 Added 0.85%	19,745 $834,000
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $396,846 - $830,890	19,578 New	19,578 $830,000
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $158,457 - $234,569	-6,630 Reduced 48.57%	7,021 $223,000
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $62,846 - $97,271	-2,754 Reduced 16.79%	13,651 $332,000
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $189,744 - $239,220	-7,485 Reduced 31.33%	16,405 $517,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $31,543 - $51,236	1,237 Added 5.46%	23,890 $675,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $275,545 - $496,435	13,363 Added 143.84%	22,653 $599,000
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $218,315 - $328,680	9,290 New	9,290 $325,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.